S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
OTCMKTS:GNWSF

StageZero Life Sciences (GNWSF) Stock Price, News & Analysis

$0.04
0.00 (0.00%)
(As of 04/18/2024 ET)
Today's Range
$0.04
$0.04
50-Day Range
$0.03
$0.04
52-Week Range
$0.00
$1.27
Volume
N/A
Average Volume
26,719 shs
Market Capitalization
$2.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
GNWSF stock logo

About StageZero Life Sciences Stock (OTCMKTS:GNWSF)

StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. It also offers Aristotle, a multi-cancer panel test for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer; and COVID PCR testing and blood test analysis. StageZero Life Sciences Ltd. is headquartered in Richmond Hill, Canada.

GNWSF Stock Price History

GNWSF Stock News Headlines

Your Next Portfolio Star: Revealing 2024's Top Stock Pick
We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)
In life sciences, Boston continues to reign supreme
Your Next Portfolio Star: Revealing 2024's Top Stock Pick
We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)
See More Headlines
Receive GNWSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for StageZero Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic Substances
Sub-Industry
N/A
Current Symbol
OTCMKTS:GNWSF
Fax
N/A
Employees
51
Year Founded
N/A

Profitability

Net Income
$-6,860,000.00
Net Margins
-200.26%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.15 million
Book Value
($0.02) per share

Miscellaneous

Free Float
N/A
Market Cap
$2.46 million
Optionable
Not Optionable
Beta
0.28
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. James R. Howard-Tripp
    Exec. Chairman & CEO
  • Mr. Carl Solomon
    Interim Chief Financial Officer
  • Prof. Choong-Chin Liew
    Co-Founder
  • Mr. Warren Whitehead C.M.A. (Age 69)
    Chief Accountant
  • Mr. David Suria
    Sr. Scientist

GNWSF Stock Analysis - Frequently Asked Questions

How have GNWSF shares performed in 2024?

StageZero Life Sciences' stock was trading at $0.0294 on January 1st, 2024. Since then, GNWSF shares have increased by 32.7% and is now trading at $0.0390.
View the best growth stocks for 2024 here
.

How do I buy shares of StageZero Life Sciences?

Shares of GNWSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:GNWSF) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners